Patents by Inventor Kishore M. Gadde
Kishore M. Gadde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190290618Abstract: The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.Type: ApplicationFiled: February 25, 2019Publication date: September 26, 2019Inventors: Kishore M. Gadde, K. Ranga R. Krishnan
-
Publication number: 20190262318Abstract: The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.Type: ApplicationFiled: March 5, 2019Publication date: August 29, 2019Inventors: Kishore M. Gadde, K. Ranga R. Krishnan
-
Publication number: 20150320726Abstract: The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.Type: ApplicationFiled: March 19, 2015Publication date: November 12, 2015Inventors: Kishore M. Gadde, K. Ranga R. Krishnan
-
Publication number: 20140364468Abstract: The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.Type: ApplicationFiled: August 20, 2014Publication date: December 11, 2014Inventors: Kishore M. Gadde, K. Ranga R. Krishnan
-
Publication number: 20110098289Abstract: The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.Type: ApplicationFiled: January 6, 2011Publication date: April 28, 2011Inventors: Kishore M. Gadde, K. Ranga R. Krishnan
-
Publication number: 20100179129Abstract: Disclosed are pharmaceutical compositions comprising mirtazapine and an anticonvulsant drug. Also disclosed are methods of preventing weight gain associated with the administration of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug. Further disclosed are methods of increasing the efficacy of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug.Type: ApplicationFiled: March 26, 2010Publication date: July 15, 2010Inventors: K. Ranga R. Krishnan, Kishore M. Gadde
-
Patent number: 7754748Abstract: The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.Type: GrantFiled: September 5, 2008Date of Patent: July 13, 2010Assignee: Duke UniversityInventors: Kishore M. Gadde, K. Ranga R. Krishnan
-
Patent number: 7713959Abstract: Disclosed are pharmaceutical compositions comprising mirtazapine and an anticonvulsant drug. Also disclosed are methods of preventing weight gain associated with the administration of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug. Further disclosed are methods of increasing the efficacy of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug.Type: GrantFiled: August 31, 2005Date of Patent: May 11, 2010Assignee: Duke UniversityInventors: K. Ranga R. Krishnan, Kishore M. Gadde
-
Publication number: 20090076108Abstract: The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.Type: ApplicationFiled: November 5, 2008Publication date: March 19, 2009Applicant: Orexigen Therapeutics, Inc.Inventors: Kishore M. Gadde, K. Ranga R. Krishnan
-
Publication number: 20090018115Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a psychotherapeutic agent and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with a psychotherapeutic agent and an anticonvulsant.Type: ApplicationFiled: September 26, 2008Publication date: January 15, 2009Applicant: Orexigen Therapeutics, Inc.Inventors: Kishore M. Gadde, K. Ranga Krishnan
-
Publication number: 20080319036Abstract: The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.Type: ApplicationFiled: September 5, 2008Publication date: December 25, 2008Applicant: Duke UniversityInventors: Kishore M. Gadde, K. Ranga R. Krishnan
-
Patent number: 7429580Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a psychotherapeutic agent and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with a psychotherapeutic agent and an anticonvulsant.Type: GrantFiled: January 11, 2005Date of Patent: September 30, 2008Assignees: Orexigen Therapeutics, Inc., Duke UniversityInventors: Kishore M. Gadde, K. Ranga R. Krishnan
-
Patent number: 7425571Abstract: The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.Type: GrantFiled: April 23, 2004Date of Patent: September 16, 2008Assignee: Orexigen Therapeutics, Inc.Inventors: Kishore M. Gadde, K. Ranga R. Krishnan
-
Publication number: 20080188476Abstract: The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.Type: ApplicationFiled: May 5, 2006Publication date: August 7, 2008Inventors: Kishore M. Gadde, K. Ranga R. Krishnan
-
Patent number: 7109198Abstract: The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.Type: GrantFiled: May 19, 2003Date of Patent: September 19, 2006Assignee: Duke UniversityInventors: Kishore M. Gadde, K. Ranga R. Krishnan
-
Publication number: 20040198668Abstract: The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.Type: ApplicationFiled: April 23, 2004Publication date: October 7, 2004Applicant: DUKE UNIVERSITYInventors: Kishore M. Gadde, K. Ranga R. Kaishnan
-
Publication number: 20040033965Abstract: The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.Type: ApplicationFiled: May 19, 2003Publication date: February 19, 2004Inventors: Kishore M. Gadde, K. Ranga R. Krishnan